Portola Pharmaceuticals Inc Reaches New 12-Month High at $29.36 (PTLA)
Portola Pharmaceuticals (NASDAQ:PTLA)’s share price reached a new 52-week high on Wednesday, Analyst Ratings.Net reports. The company traded as high as $29.36 and last traded at $29.03, with a volume of 53,869 shares traded. The stock had previously closed at $27.36.
Separately, analysts at Cowen and Company raised their price target on shares of Portola Pharmaceuticals (NASDAQ:PTLA) from $45.37 to $47.00 in a research note to investors on Friday, August 16th. They now have an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, Portola Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $38.50.
Portola Pharmaceuticals has a one year low of $14.75 and a one year high of $28.77. The stock’s 50-day moving average is $24.17 and its 200-day moving average is $22.68. The company’s market cap is $1.020 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Thursday, August 15th. The company reported ($1.47) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.75. On average, analysts predict that Portola Pharmaceuticals will post $-3.60 earnings per share for the current fiscal year.
Portola Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who has limited or no approved treatment options.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.